α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume.
OBJECTIVE
To examine the mechanism underlying improvements in nocturia by α(1)-blockers, we investigated whether the α(1)-blocker naftopidil acts on nocturia with sleep disturbance using a frequency/volume chart (FVC).


METHODS
A total of 56 male patients with lower urinary tract symptoms were enrolled. The inclusion criteria were as follows: eight or more points on the I-PSS; three or more points on the I-PSS score for nocturia; and prostate volume larger than 20 ml. Patients received 50 mg of naftopidil once daily for 4 weeks, and non-responders received 75 mg for another 4 weeks. All patients were examined, and their data entered into FVC for 2 days before and after administration of naftopidil. Quality of sleep was also evaluated using modified Pittsburgh sleep quality index (PSQI).


RESULTS
Patients with sleep quality scores of three or four were assigned to sleep disturbance group (n = 33), while those with scores of less than three were assigned to non-disturbance group (n = 23). After administration of naftopidil, total I-PSS decreased and nocturia score decreased from 3.5 to 2.6 (P < 0.01). Total mean score of modified PSQI in sleep disturbance group became significantly lower after administration of naftopidil (from 16.9 to 14.0; P < 0.01). Naftopidil significantly decreased nocturnal urine volume, resulting in a decrease in the nocturnal polyuria index in both sleep disturbance and non-disturbance groups.


CONCLUSIONS
These results suggest that α(1)-blockers have the ability to normalize sleep disorders. Naftopidil improved nocturnal polyuria regardless of the presence of sleep disturbance, meaning that it might directly reduce nocturnal urine production.
Yokoyama
Osamu
O
Department of Urology, Faculty of Medical Science, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji, Fukui, 910-1193, Japan. oyoko@u-fukui.ac.jp
Aoki
Yoshitaka
Y
Tsujimura
Akira
A
Takao
Tetsuya
T
Namiki
Mikio
M
Okuyama
Akihiko
A
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D053158:Nocturia / Q000150:complications / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D015995:Prevalence; D011788:Quality of Life; D012893:Sleep Wake Disorders / Q000453:epidemiology* / Q000209:etiology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D058668:Adrenergic alpha-1 Receptor Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil
Jpn J Pharmacol. 1999 Apr;79(4):447-54
10361884
J Urol. 2000 Jan;163(1):5-12
10604303
J Psychosom Res. 2004 May;56(5):517-25
15172208
BJU Int. 2006 May;97(5):1017-23
16643483
BJU Int. 2008 Apr;101(7):847-52
18321317
Int J Urol. 2008 Dec;15(12):1049-54
19120513
J Urol. 2005 Jul;174(1):370-4
15947692
Endocrinology. 1984 Apr;114(4):1426-32
6323145
Neurourol Urodyn. 2006;25(5):461-7
16673377
Endocrinology. 1987 Jun;120(6):2227-33
3032579
J Am Geriatr Soc. 1995 Sep;43(9):985-92
7544816
Neurourol Urodyn. 2002;21(2):179-83
11857672
Eur Urol. 2009 Feb;55(2):472-9
18583022
J Gerontol A Biol Sci Med Sci. 1996 May;51(3):M108-15
8630703
Gen Pharmacol. 1995 Oct;26(6):1203-9
7590108
J Urol. 2003 Jul;170(1):145-8
12796667
Int J Urol. 2006 Jan;13(1):15-20
16448426
Scand J Urol Nephrol. 1992;26(4):345-9
1292071
Urology. 2008 Nov;72(5):1051-5
18817955
Urology. 2006 Jun;67(6):1188-92
16750254
J Urol. 1999 Jan;161(1):133-8
10037385
J Urol. 2002 Mar;167(3):1513-21
11832780
BJU Int. 2006 Apr;97(4):747-51, discussion 751
16536766
Pharmacol Rev. 1994 Jun;46(2):121-36
7938162
Brain Res Mol Brain Res. 1999 Jan 8;63(2):254-61
9878769